Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) — Cash Flow Reinvestment Rate
Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has a Cash Flow Reinvestment Rate of 1.44x as of September 2025, reinvesting CN¥16.64 Million (capex CN¥16.64 Million ) from operating cash flow of CN¥11.57 Million. See 301211 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Cash Flow Reinvestment Rate (2018–2025)
Historical reinvestment intensity for Hubei Biocause Heilen Pharmaceutical Co. Ltd. across 8 annual periods. For the full cash flow conversion analysis, see 301211 cash flow conversion.
Annual Cash Flow Reinvestment Rate for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2018–2025)
Year-by-year capital reinvestment analysis for Hubei Biocause Heilen Pharmaceutical Co. Ltd.. See 301211 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 8.92x | CN¥67.34 Million | CN¥7.55 Million | CN¥52.33 Million | ▼ -22.8% |
| 2024 | 11.55x | CN¥1.11 Billion | CN¥96.07 Million | CN¥164.43 Million | ▲ +661.3% |
| 2023 | 1.52x | CN¥207.94 Million | CN¥137.06 Million | CN¥186.53 Million | ▲ +48.7% |
| 2022 | 1.02x | CN¥255.82 Million | CN¥250.79 Million | CN¥75.95 Million | ▼ -49.6% |
| 2021 | 2.02x | CN¥250.71 Million | CN¥123.98 Million | CN¥21.07 Million | ▲ +326.1% |
| 2020 | 0.47x | CN¥57.74 Million | CN¥121.67 Million | CN¥13.39 Million | ▼ -38.7% |
| 2019 | 0.77x | CN¥288.37 Million | CN¥372.33 Million | CN¥32.34 Million | ▲ +135.3% |
| 2018 | 0.33x | CN¥25.08 Million | CN¥76.18 Million | CN¥25.08 Million | — |